A phase II clinical trial evaluating the efficacy and safety of osimertinib combined with bevacizumab in patients with EGFR-mutant non-small cell lung cancer (NSCLC) with MPE demonstrated good safety but failed to significantly prolong progression-free survival (PFS) (49). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.